Early access

BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir

23 May 2018. Related: Early access, Pregnancy, Side effects.

EMA approves dolutegravir/rilpivirine (Juluca) in Europe as dual-therapy HIV switch option

21 May 2018. Related: Early access, Antiretrovirals.